Segasist Technologies, a MaRS Discovery District Client, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Prostate Auto-Contouring software 'Segasist P-AC'.
Profound Medical Inc, a MaRS client hopes to improve quality of life for men with prostate cancer by developing a faster, more precise treatment aimed at reducing side effects. Profound Medical won the $200,000 Premier's Catalyst Award for a start-up company with the best innovation.
Avenir Medical Inc, a MaRS Client was named Ontario's Next Top Entrepreneur at the conference of the Ontario Centres of Excellence.
"Jack Stewart a biotechnology entrepreneur, is about to start a human trial for a drug developed from a compound found in shrew spit that could treat ovarian, breast and prostate cancers without many of the side effects of chemotherapy." Veronika Litinski, a Senior Advisor at MaRS in the Life Science and Health care practice says it is difficult to run trials with a clear robust criteria.